5 CEFs Set to End 2018 With Big Gains (and 8.2% dividends)

Our Archive

Search completed

We’ve seen a lot of volatility and fear in 2018, and that’s handed us a great buying opportunity—particularly in the 5 unloved funds I’ll show you below.

Make no mistake: each of these 5 despised funds is poised for serious upside before 2018 is out … and they’ll pay us 8.2% average dividends, to boot. That’s enough to hand you $3,400 a month on a $500k nest egg! Before we get to them, let’s take a look back at the year so far and see what’s handed us this terrific opportunity.

History Is Set to Repeat

If you bought closed-end funds (CEFs) back in early March, when the market tanked and I urged investors to buy, you’d be enjoying a nice double-digit total return in just 6 months:

Hated CEFs Turn the Corner

Why did these 3 funds—the Reaves Utility Income Fund (UTG), the Cohen & Steers Infrastructure Fund (UTF) and the DNP Select Income Fund (DNP)—all of which I recommended back on March 1—soar?… Read more

Read More

Today I want to show you a beaten-down sector that has a long history of crushing the market—and 4 funds that should be on your radar now.

These 4 funds are a great place to pocket dividends up to 10.9% (or $10,900 a year on a $100k investment) while you wait for the market to realize that it’s discounting their industry far too much.

I’m talking about 4 standout fund buys from the biotech sector.

Biotech has fallen over 10% from its 2018 high and is now down a bit more than the broader market. Just look at the iShares Nasdaq Biotechnology ETF (IBB) vs.…
Read more

Read More

Categories